194 related articles for article (PubMed ID: 25997551)
1. Successful use of infliximab and tacrolimus in a patient with Crohn's disease.
Cortes X; Borrás-Blasco J; Rodríguez J; Moreno M; Molés JR; Castera E
Int J Clin Pharmacol Ther; 2015 Aug; 53(8):692-6. PubMed ID: 25997551
[TBL] [Abstract][Full Text] [Related]
2. Successful use of infliximab and tacrolimus combination therapy in a patient with ulcerative colitis refractory to infliximab dose intensification plus azathioprine.
Cortes X; Borrás-Blasco J; Fernendez S; Moreno M; Rodríguez J; Molés JR; Casterá E
Int J Clin Pharmacol Ther; 2016 Feb; 54(2):125-8. PubMed ID: 26754306
[TBL] [Abstract][Full Text] [Related]
3. Elective switching from infliximab to adalimumab in stable Crohn's disease.
Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
[TBL] [Abstract][Full Text] [Related]
4. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis.
Saito S; Shimizu U; Nan Z; Mandai N; Yokoyama J; Terajima K; Akazawa K
J Crohns Colitis; 2013 Mar; 7(2):167-74. PubMed ID: 22626508
[TBL] [Abstract][Full Text] [Related]
5. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
D'Haens GR; Panaccione R; Higgins PD; Vermeire S; Gassull M; Chowers Y; Hanauer SB; Herfarth H; Hommes DW; Kamm M; Löfberg R; Quary A; Sands B; Sood A; Watermeyer G; Lashner B; Lémann M; Plevy S; Reinisch W; Schreiber S; Siegel C; Targan S; Watanabe M; Feagan B; Sandborn WJ; Colombel JF; Travis S
Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814
[TBL] [Abstract][Full Text] [Related]
6. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
7. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease.
Kierkuś J; Iwańczak B; Wegner A; Dadalski M; Grzybowska-Chlebowczyk U; Łazowska I; Maślana J; Toporowska-Kowalska E; Czaja-Bulsa G; Mierzwa G; Korczowski B; Czkwianianc E; Żabka A; Szymańska E; Krzesiek E; Więcek S; Sładek M
J Pediatr Gastroenterol Nutr; 2015 May; 60(5):580-5. PubMed ID: 25564804
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
Vermeire S; Noman M; Van Assche G; Baert F; D'Haens G; Rutgeerts P
Gut; 2007 Sep; 56(9):1226-31. PubMed ID: 17229796
[TBL] [Abstract][Full Text] [Related]
9. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.
Mantzaris GJ; Viazis N; Petraki K; Papamichael K; Theodoropoulos I; Roussos A; Karakoidas C; Koilakou S; Raptis N; Smyrnidis A; Agalos G; Karamanolis DG
Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1042-8. PubMed ID: 20139856
[TBL] [Abstract][Full Text] [Related]
10. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease.
Sinitsky DM; Lemberg DA; Leach ST; Bohane TD; Jackson R; Day AS
J Gastroenterol Hepatol; 2010 Apr; 25(4):810-6. PubMed ID: 20492339
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.
Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
Gut; 2009 Apr; 58(4):492-500. PubMed ID: 18832518
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
[TBL] [Abstract][Full Text] [Related]
13. Infliximab treatment of pediatric refractory Crohn's disease: a case report.
Akman SA; Arikan C; Sözen G; Oztürk C; Yağci RV
Turk J Gastroenterol; 2006 Jun; 17(2):133-6. PubMed ID: 16830299
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy.
Ruemmele FM; Lachaux A; Cézard JP; Morali A; Maurage C; Giniès JL; Viola S; Goulet O; Lamireau T; Scaillon M; Breton A; Sarles J;
Inflamm Bowel Dis; 2009 Mar; 15(3):388-94. PubMed ID: 19023899
[TBL] [Abstract][Full Text] [Related]
15. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn's Disease: Experience from a Tertiary Medical Center in China.
Zhang T; Wang Z; Fan R; Zhang M; Lin Y; Hong L; Zhou X; Hu S; Cheng M; Zhong J
Biomed Res Int; 2016; 2016():8648307. PubMed ID: 27896276
[No Abstract] [Full Text] [Related]
17. 12-month follow-up after successful infliximab therapy in pediatric crohn disease.
Wynands J; Belbouab R; Candon S; Talbotec C; Mougenot JF; Chatenoud L; Schmitz J; Cézard JP; Goulet O; Hugot JP; Ruemmele FM
J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):293-8. PubMed ID: 18376247
[TBL] [Abstract][Full Text] [Related]
18. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
[TBL] [Abstract][Full Text] [Related]
19. A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis.
Yamagami H; Nishida Y; Nagami Y; Hosomi S; Yukawa T; Otani K; Tanaka F; Taira K; Kamata N; Tanigawa T; Shiba M; Watanabe T; Fujiwara Y
Rom J Intern Med; 2017 Sep; 55(3):151-157. PubMed ID: 28222041
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
